Clinical trials
Phase 2 clinical trials
Below are recruiting phase 2 clinical trials, each written for real people, not researchers. We’re tracking 295 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06023758RecruitingPhase 2
Study of two drugs with or without chemo for HER2-positive stomach cancer
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06256237RecruitingPhase 2
Immunotherapy plus chemo before surgery for limited-stage small cell lung cancer
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
ShanghaiAges 18 years+ - NCT07812090RecruitingPhase 2
Oral medication for diabetic macular edema
This study tests an oral medication that may reduce swelling in the retina caused by diabetes. If you have diabetic macular edema affecting your central vision, this trial could help you preserve or improve your sight.
McAllen, TexasAges 18–75 - NCT07811726RecruitingPhase 2
Eye drops for wet age-related macular degeneration
This trial tests a new eye drop called NT-101 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if the drops can improve vision and reduce fluid in the eye, possibly as a less invasive alternative to injections.
Bonita Springs, FloridaAges 50 years+ - NCT07803822RecruitingPhase 2
New drug alone or with inclisiran for high cholesterol and triglycerides
This study tests a new investigational drug called MWX203, given alone or with another medicine (inclisiran), to lower both 'bad' cholesterol (LDL) and triglycerides in people with mixed dyslipidemia. The goal is to see if the combination is safe and works better than statins alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06529237Recruiting
Malaria study for children and pregnant women in Mozambique
This study looks at how malaria spreads in Mozambique by testing children and pregnant women with fever. If you or your child may have malaria, participating could help researchers understand and fight the disease better.
Manhiça, Maputo ProvinceAges 6 months+ - NCT07766018RecruitingPhase 2
Elacestrant for advanced or metastatic breast cancer
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
ChibaAges 18 years+ - NCT06493760RecruitingPhase 2
Testing a new drug for advanced colorectal cancer
This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07743112RecruitingPhase 2
Study of a new drug combo for untreated acute myeloid leukemia
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
TianjinAges 18 years+ - NCT06621277Recruiting
Improving care for young adults with GI cancer
This study aims to improve care for younger adults (ages 18-50) with gastrointestinal (GI) tumors. Researchers will test ways to better support patients during and after treatment. If you are 18-50 and being treated for a GI tumor at Heidelberg University Hospital, you may be able to join.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT07681089RecruitingPhase 2
Foscenvivint for HIV/HCV cirrhosis with hemophilia
This trial tests a drug called foscenvivint for people with hemophilia and liver cirrhosis caused by both HIV and hepatitis C (already treated). The study aims to see if it can help improve liver health.
Sapporo, HokkaidoAges 18–79 - NCT07679893RecruitingPhase 2
Inhaled nintedanib for idiopathic pulmonary fibrosis
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Windsor, OntarioAges 40–80 - NCT07649070RecruitingPhase 2
Virus therapy and low-dose radiation for children with aggressive brain cancer
This trial tests whether a special herpes virus (G207) combined with low-dose radiation can help children with high-grade brain tumors (gliomas). The virus is injected into the tumor to attack the cancer cells while radiation helps boost the effect.
Houston, TexasAges 3–21 - NCT07649681Recruiting
AI nutrition help for taste changes from cancer treatment
This study tests whether an AI-powered nutrition program can help people with taste changes caused by cancer therapy. You'll get personalized recipe suggestions and nutrition advice through an online portal to help you eat better during treatment.
Augsburg, BavariaAges 18 years+ - NCT07644559RecruitingPhase 2
Study of VS-7375 with cetuximab for advanced pancreatic cancer
This trial tests a new drug combination for people with a specific KRAS mutation in pancreatic cancer. It aims to see if the treatment can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06632262RecruitingPhase 2
Testing new drugs for cancers with FGFR gene changes
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
Guiyang, GuizhouAges 18 years+ - NCT07623616RecruitingPhase 2
Ziftomenib for relapsed AML with NPM1 mutation
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
ChibaAges 18 years+ - NCT07570862RecruitingPhase 2
CAR T-Cell Therapy for Hard-to-Treat Lupus Kidney Disease
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Beverly Hills, CaliforniaAges 12–70 - NCT07575308RecruitingPhase 2
ALN-6400 for Heavy Bleeding in von Willebrand Disease
This trial tests a new medicine called ALN-6400 in teenage and adult women with von Willebrand disease (a blood clotting condition) who experience heavy menstrual bleeding. The goal is to see if this treatment can reduce bleeding and improve quality of life.
Orange, CaliforniaAges 16–45 - NCT06668103RecruitingPhase 2
Study of ABSK043 and Firmonertinib for EGFR-mutant lung cancer
This study tests a new combination of two targeted therapies (ABSK043 and firmonertinib) for people with a specific type of advanced lung cancer. It is for patients whose tumors have an EGFR mutation and are PD-L1 positive.
Hefei, AnhuiAges 18 years+ - NCT07562581RecruitingPhase 2
Two Drugs for Advanced Lung Cancer With KRAS Mutation
This trial tests two drugs (luvometinib and anlotinib) together to treat advanced lung cancer that has a KRAS mutation and has grown despite previous treatment. The goal is to see if this combination helps patients live longer and slows cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07566364RecruitingPhase 2
Mosunetuzumab for Chronic Lymphocytic Leukemia with Minimal Residual Disease
This study tests a new antibody drug called mosunetuzumab in patients with chronic lymphocytic leukemia (CLL) who have already tried other treatments and still have detectable leukemia cells in their bone marrow. The drug is designed to work in a way that might help your immune system fight the remaining cancer cells.
Houston, TexasAges 18 years+ - NCT07552077RecruitingPhase 2
Sirolimus Gel for Angiokeratoma Treatment
This trial tests a topical gel (a cream you apply to skin) containing sirolimus to treat angiokeratomas, which are small growths on the skin. The goal is to see if this treatment is safe and effective.
Sherman Oaks, CaliforniaAges 6 years+ - NCT07535034RecruitingPhase 2
Testing Dotinurad for Gout in People Who Can't Take Other Medications
This trial tests a new drug called dotinurad for gout patients whose standard medications either don't work or cause side effects. Dotinurad works differently by helping your body get rid of uric acid (the substance that causes gout attacks), and the study will see if it safely lowers uric acid levels.
Birmingham, AlabamaAges 18–75
Hear when a new Phase 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2?
- Yes. Clin2 currently lists 295 recruiting phase 2 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.